If your rheumatology practice runs an infusion suite, you already know it is a different animal from regular office visit billing. You are not just billing for a service, you are billing for a drug that your practice bought, stored, and administered. Get any piece of that wrong and you can lose real money on a single patient visit.
Let's walk through how buy and bill actually works, where the risk sits, and what to check on every remittance (the payer's payment report, often called an EOB or ERA) before you move on to the next claim.
What "Buy and Bill" Actually Means
In the buy and bill model, your practice purchases the infusion drug directly from a distributor or specialty pharmacy, stores it, administers it to the patient, and then bills the payer for both the drug and the service of giving it. This is different from "white bagging," where the pharmacy ships the drug straight to your office already billed to the patient's insurance, or "brown bagging," where the patient brings the drug in themselves.
Buy and bill puts your practice on the hook for the upfront cost of expensive biologics like infliximab, tocilizumab, or abatacept. That is a real cash outlay before you ever see a payment. It is also why getting reimbursed correctly and on time matters so much more here than for a typical office visit.
J-Codes: The Billing Codes That Carry the Drug Cost
J-codes are the specific billing codes (part of the HCPCS code set) used to bill for injectable and infused drugs. Each drug has its own J-code, and many of them specify a set dosage unit, like "per 10 mg." If the patient's actual dose does not match the code's unit, you have to calculate and report the correct number of units.
This is one of the most common places rheumatology practices lose money without realizing it. Bill the wrong number of units, use an outdated J-code after a payer update, or forget to bill for drug wastage (the leftover drug in a single-use vial that could not be used) and you either get denied or get paid less than what the drug actually cost you.
Say your practice draws 375 mg from a 400 mg single-use vial for a patient. As an example only, if your payer allows billing for the wasted 25 mg with the correct modifier, and you skip that step, you have essentially given away that portion of the drug for free.
Prior Authorization on High-Cost Biologics
Prior authorization (getting the payer's approval before treatment) is standard on nearly every biologic used in rheumatology. Payers want to confirm the diagnosis, prior treatment history, and dosing plan before they agree to pay for a drug that can cost thousands of dollars per infusion.
The tricky part is that prior auths for infusion drugs are usually approved for a specific number of visits or a specific date range. If a patient's infusion schedule shifts, or the payer's authorization window lapses, you can do everything else right and still get denied for an expired or exhausted authorization.
A few things worth building into your workflow:
- Track authorization end dates against the patient's actual infusion calendar, not just the date it was approved.
- Confirm the approved units and dosage match what is actually being billed, since payers sometimes approve a lower dose than what is administered.
- Reverify before renewal infusions, especially if the patient had any dose changes or a treatment gap.
Getting this piece wrong is one of the fastest ways to end up with a denied claim, and denials on high-cost drugs are especially painful. We broke down the real cost of a denied claim in this post, and infusion denials sit at the expensive end of that math.
Why Underpayments Hurt More on Infusions Than Anywhere Else
Here is the part that catches a lot of practices off guard. An underpayment on a routine office visit might cost you a small difference between the contracted rate and what actually paid. An underpayment on an infusion claim can mean you are paid less than what you spent buying the drug in the first place.
Say your practice paid a certain amount for a vial of a biologic, as a labeled example only, and the payer reimburses at a rate that does not fully cover the drug cost plus the nursing time and supplies to administer it. You are not just missing profit, you may be losing money on that visit before you even factor in staff time.
This is why infusion claims deserve more scrutiny per claim than almost anything else in your billing workflow. A high clean claim rate (the percentage of claims paid correctly on first submission) matters everywhere, but on infusions the dollar impact of getting it wrong is amplified. If you want a deeper look at what that metric actually measures and why it matters, our clean claim rate guide is a good next read.
What to Double-Check on Every Remit
Before you file an infusion remit away as done, walk through these checks. It takes a few extra minutes per claim and it consistently catches money that would otherwise slip through.
- Drug reimbursement versus your actual acquisition cost. Compare the paid amount for the J-code line against what your practice paid for that drug.
- Units paid versus units billed. Payers sometimes reduce the unit count without a clear denial reason, which quietly shrinks your payment.
- Administration code payment. The infusion administration codes (billed separately from the drug itself) should be paid according to your contracted rate, not bundled or reduced without explanation.
- Wastage line items. If you billed for drug wastage, confirm it was actually paid and not silently denied.
- Modifier handling. Confirm modifiers for wastage, multiple units, or sequential infusions processed the way your contract says they should.
None of this is glamorous work, but it is exactly the kind of repetitive, detail-heavy checking that AI tools are well suited for, since they can flag a mismatch between paid units and billed units in seconds instead of a person scanning line by line. If you are curious how that kind of automation fits into denial prevention more broadly, we covered it in this piece.
Building a Habit Around This, Not a One-Time Fix
The practices that do well with buy and bill infusion billing are not the ones with the fanciest software. They are the ones who treat remit review as a non-negotiable step, every claim, every time, because they know exactly how much is at stake on each infusion visit.
If you want a clearer picture of where your own infusion claims might be leaking revenue, right now, without changing anything about how you bill, AutomatedRCM offers a free Billing Health Check at audit.getautomatedrcm.com. It is a straightforward way to see where the gaps are before you decide what to do about them.
Frequently Asked Questions
What does buy and bill mean in infusion billing?
Buy and bill means the practice purchases the infusion drug itself, administers it to the patient, and then bills the insurance payer for both the drug cost and the administration service. This is different from having a pharmacy ship the drug already billed to the patient's plan.
What is a J-code and why does it matter for rheumatology infusions?
A J-code is a specific billing code used for injectable and infused drugs, and each drug has its own code tied to a set dosage unit. Billing the wrong number of units or using an outdated J-code is one of the most common reasons infusion claims get denied or underpaid.
Why do infusion claims lose more money than regular office visits when underpaid?
Because the practice already paid upfront for the drug before administering it, an underpayment on an infusion claim can mean the practice is reimbursed for less than the drug actually cost. On a regular office visit there is no comparable upfront drug expense at risk.
What should I check first on an infusion remittance advice?
Start by comparing the paid amount for the drug's J-code against what the practice actually paid to acquire that drug, then confirm the billed units matched the paid units. Also check that the administration code and any wastage modifiers were paid according to the payer contract.